Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1–mediated transcriptional events
Jai-Hyun Kim(The University of Texas MD Anderson Cancer Center), Ho‐Young Lee(Cancer Clinic)
Cited by 75
Related Papers
Molecular targeted therapy for anticancer treatment
|Experimental & Molecular Medicine|2022|495
Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib
|Cancer Research|2006|336
Effects of Deguelin on the Phosphatidylinositol 3-Kinase/Akt Pathway and Apoptosis in Premalignant Human Bronchial Epithelial Cells
|JNCI Journal of the National Cancer Institute|2003|257
Design, Synthesis, and Biological Evaluation of Novel Deguelin-Based Heat Shock Protein 90 (HSP90) Inhibitors Targeting Proliferation and Angiogenesis
|Journal of Medicinal Chemistry|2012|102
Hypoxia-inducible Factor 1α and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer
|JNCI Journal of the National Cancer Institute|2005|97